Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/41346
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMarcianes, Patricia
dc.contributor.authorNegro, Sofia
dc.contributor.authorGarcía-García, Luis
dc.contributor.authorMontejo, Consuelo
dc.contributor.authorBarcia, Emilia
dc.contributor.authorFernández-Carballido, Ana
dc.date.accessioned2019-08-01T12:01:41Z-
dc.date.available2019-08-01T12:01:41Z-
dc.date.issued2017
dc.identifier.citationInt J Nanomedicine.2017;(12):1959-1968
dc.identifier.urihttps://hdl.handle.net/20.500.12530/41346-
dc.description.abstractA new nanocarrier is developed for the passage of gatifloxacin through the blood-brain barrier to treat central nervous system tuberculosis. Gatifloxacin nanoparticles were prepared by nanoprecipitation using poly(lactic-co-glycolic acid) (PLGA) 502 and polysorbate 80 or Labrafil as surface modifiers. The evaluation of in vivo blood-brain barrier transport was carried out in male Wistar rats using rhodamine-loaded PLGA nanoparticles prepared with and without the surface modifiers. At 30 and 60 minutes after administration, nanoparticle biodistribution into the brain (hippocampus and cortex), lungs, and liver was studied. The results obtained from the cerebral cortex and hippocampus showed that functionalization of rhodamine nanoparticles significantly increased their passage into the central nervous system. At 60 minutes, rhodamine concentrations decreased in both the lungs and the liver but were still high in the cerebral cortex. To distinguish the effect between the surfactants, gatifloxacin-loaded PLGA nanoparticles were prepared. The best results corresponded to the formulation prepared with polysorbate 80 with regard to encapsulation efficiency (28.2%), particle size (176.5 nm), and ζ-potential (-20.1 mV), thereby resulting in a promising drug delivery system to treat cerebral tuberculosis.
dc.language.isoeng
dc.rightsopenAccess-
dc.subjectLabrafil
dc.subjectblood–brain barrier
dc.subjectbrain delivery
dc.subjectgatifloxacin
dc.subjectnanoparticles
dc.subjectpolysorbate 80
dc.subjecttargeting
dc.subject.meshAnimals
dc.subject.meshCerebral Cortex
dc.subject.meshChemistry, Pharmaceutical
dc.subject.meshFluoroquinolones
dc.subject.meshGatifloxacin
dc.subject.meshMale
dc.subject.meshMicroscopy, Confocal
dc.subject.meshNanoparticles
dc.subject.meshNeurons
dc.subject.meshRats, Wistar
dc.subject.meshRhodamines
dc.subject.meshSolutions
dc.subject.meshTissue Distribution
dc.subject.meshTuberculosis, Central Nervous System
dc.titleSurface-modified gatifloxacin nanoparticles with potential for treating central nervous system tuberculosis.
dc.typeArtículo
dc.identifier.pubmedID28331318
dc.format.volume12
dc.format.page1959-1968
dc.identifier.e-issn1178-2013
dc.identifier.journalInternational journal of nanomedicine
dc.identifier.doi10.2147/IJN.S130908
dc.identifier.pmcPMC5357078
dc.pubmedtypeJournal Article
Appears in Collections:Fundaciones e Institutos de Investigación > IIS H. U. Clínico San Carlos > Artículos

Files in This Item:
File Description SizeFormat 
PMC5357078.pdf1.6 MBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.